Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, Dose-escalating, Clinical and Pharmacokinetic Study of Humanized Сhimeric Anti-CD47 Antibody in Patients With Verified Diagnosis of Breast Cancer

Next Previous
Search
Trial Profile

Phase I, Dose-escalating, Clinical and Pharmacokinetic Study of Humanized Сhimeric Anti-CD47 Antibody in Patients With Verified Diagnosis of Breast Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CC 90002 (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Acronyms ASSIST-II

Most Recent Events

  • 31 Aug 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
  • 27 Aug 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Aug 2015, according to ClinicalTrials.gov record.
  • 06 Jul 2015 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top